Click on image to view larger version.

Figure 3 Rates of all-cause mortality (D), myocardial infarction (MI), or severe recurrent ischemia leading to urgent revascularization (UR) through 14 days in the unfractionated heparin (UFH) and enoxaparin (ENOX) treatment groups in the pooled Thrombolysis In Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non–Q-wave Coronary Events (ESSENCE) trial populations, with patients stratified by TIMI risk score. NSTEMI = non–ST-segment elevation myocardial infarction; % Popl’n = percent of overall trial population with that TIMI risk score; UA = unstable angina.